Thymosin Alpha-1 for Health & Longevity - Quick Reference Sheet
evipedia.ai ← Back

Thymosin Alpha-1 for Health & Longevity

Created on 08/08/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

A laboratory-made copy of a signaling molecule from the thymus gland, which shrinks with age. The strongest measured effects are in people whose immune systems are already depleted; use for slowing immune aging in healthy adults has never been tested. Consistently well tolerated, with injection-site reactions dominating. Product quality and years-long use remain open questions. (Full Review)

Protocol

Standard licensed regimen
1.6 mg twice weekly
Subcutaneous, 900 μg/m² body surface area, for 6 to 12 months. The only regimen with regulatory endorsement.
Competing approaches — conventional versus longevity-clinic practice
450 μg to 1.6 mg daily
Repeated 4 to 12 week blocks for immune maintenance in people who are not ill. No controlled evidence at all.
Best time of day
Evening or morning
No study of dosing time exists. Evening is more defensible on tolerability grounds, morning on mechanistic.
Time to effect
Immune markers
3 to 7 days
Monocyte HLA-DR recovery by day 3, clear by day 7; CD4+ counts rose within five days.
Hepatitis outcomes
6 to 12 months
Often continue improving after dosing stops.
Vaccine antibody responses
3 to 6 weeks
Antibody titers when given alongside a vaccine; all positive studies are in impaired responders.

Benefits

Contraindications
  • Solid organ transplant recipients on any maintenance immunosuppression (especially within 12 months of transplant)
  • Active autoimmune disease requiring systemic immunosuppression
  • Untreated Graves' disease
  • Checkpoint inhibitor therapy with a prior grade 2 or higher immune-related adverse event
  • Pregnancy and breastfeeding
  • Children outside specialist management of congenital thymic disorders
  • Decompensated cirrhosis (Child-Pugh Class C)
  • Documented hypersensitivity to the peptide or to mannitol
    •
Key Interactions
  • Immunosuppressants (cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, sirolimus, everolimus)
  • Systemic corticosteroids (prednisone, dexamethasone, methylprednisolone)
  • Immune checkpoint inhibitors (pembrolizumab, nivolumab, sintilimab, ipilimumab)
  • Interferon alfa and interleukin-2 (peginterferon alfa-2a, aldesleukin)
  • Live attenuated vaccines (measles-mumps-rubella, varicella, live attenuated influenza, yellow fever)
  • High-dose non-steroidal anti-inflammatories and antihistamines (ibuprofen, naproxen, cetirizine, loratadine)
  • Immune-stimulating supplements (echinacea, astragalus, turkey tail, AHCC, bovine colostrum, high-dose zinc)
  • High-dose omega-3 fatty acids, curcumin, very high-dose vitamin D
  • Other thymic and peptide interventions (thymalin, thymopentin, thymus glandular extracts, thymosin beta-4)

Risk & Side Effects

  • High: Injection-site reactions; transient liver enzyme elevation in chronic viral hepatitis
  • Medium: Increased mortality signal in adults under 60 with severe infection; systemic flu-like symptoms and fatigue; product contamination and misidentification from unregulated supply
  • Low: Amplification of immune-related adverse events with checkpoint inhibitors; precipitation or aggravation of autoimmune disease; immunogenicity and anti-drug antibodies
  • Speculative: Promotion of occult malignancy through immune suppression pathways; unknown consequences of years of continuous use in healthy people; altered vaccine or allergen tolerance

Monitoring

Marker Target Why
Absolute lymphocyte count 1.8–3.0 × 10⁹/L Whether there is a deficit to correct
CD4+ T-cell count 700–1,200 cells/μL Rises most consistently on treatment
CD8+ T-cell count 300–600 cells/μL Completes the ratio; detects excessive expansion
CD4+/CD8+ ratio 1.5–2.5 Best marker of immune aging; inverted below 1.0
Natural killer cell count and activity 100–400 cells/μL; activity within the assay reference range Captures the innate arm the peptide also stimulates
High-sensitivity C-reactive protein Below 0.5 mg/L Inflammatory tone, and any reaction provoked
Alanine and aspartate aminotransferase ALT below 25 U/L (men), below 20 U/L (women); AST similar Separates hepatitis flare from liver injury
Neutrophil-to-lymphocyte ratio Below 2.0 Cheap composite of inflammatory and immune balance
Thyroid-stimulating hormone and thyroid peroxidase antibodies TSH 1.0–2.0 mIU/L; TPO antibodies negative Screens for autoimmune thyroid disease
Antinuclear antibody titer Negative, or below 1:80 Identifies latent autoimmunity before immune activation
Immunoglobulins G, A, and M Within the age-adjusted reference range Detects an underlying antibody deficiency
25-hydroxyvitamin D 40–60 ng/mL Cheaper correctable determinant of T-cell function
Serum thymosin alpha-1 No established functional range Whether the replaced molecule is deficient

Cadence: Baseline before the first dose; immune and safety panels at 4 and 12 weeks, then every 6 months. Liver enzymes every 4 weeks for 12 weeks in viral hepatitis; thyroid function at any new symptom.

Qualitative Assessment

  • Frequency, duration, and severity of infections over 6 to 12 months versus the preceding period
  • Recovery time from minor illnesses
  • New joint pain, morning stiffness, rash, or unexplained diarrhea as early autoimmune indicators
  • Heat intolerance, palpitations, or unexplained weight change, prompting thyroid testing
  • Post-injection malaise and sleep disruption over the first four doses, for tolerability and timing
  • Energy and cognitive clarity, the domains most susceptible to expectation effects
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.